127 related articles for article (PubMed ID: 11740998)
1. Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach.
Gandara DR; Lara PN; Lau DH; Mack P; Gumerlock PH
Lung Cancer; 2001 Dec; 34 Suppl 3():S75-80. PubMed ID: 11740998
[No Abstract] [Full Text] [Related]
2. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancer: clinical value of new biological predictors.
Graziano SL
Lung Cancer; 1997 Jun; 17 Suppl 1():S37-58. PubMed ID: 9213302
[No Abstract] [Full Text] [Related]
4. New prognostic factors in resectable non-small cell lung cancer.
Smit EF; Groen HJ; Splinter TA; Ebels T; Postmus PE
Thorax; 1996 Jun; 51(6):638-46. PubMed ID: 8693450
[No Abstract] [Full Text] [Related]
5. Prognostic molecular markers in non-small cell lung cancer.
Nikliński J; Niklińska W; Laudanski J; Chyczewska E; Chyczewski L
Lung Cancer; 2001 Dec; 34 Suppl 2():S53-8. PubMed ID: 11720742
[TBL] [Abstract][Full Text] [Related]
6. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.
Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG
J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543
[TBL] [Abstract][Full Text] [Related]
7. Genetic evolutionary staging of early non-small cell lung cancer: the P53 --> HER-2/NEU --> ras sequence.
Shackney SE; Smith CA; Pollice A; Levitt M; Magovern JA; Wiechmann RJ; Silverman J; Sweeney L; Landreneau RJ
J Thorac Cardiovasc Surg; 1999 Aug; 118(2):259-67. PubMed ID: 10424999
[TBL] [Abstract][Full Text] [Related]
8. [Genetic investigations for lung carcinoma].
Shirakusa T; Noda N; Matsuzoe D
Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):482-6. PubMed ID: 12094700
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis.
Hilbe W; Dirnhofer S; Oberwasserlechner F; Eisterer W; Ammann K; Schmid T; Hilbe G; Thaler J; Wöll E
J Clin Pathol; 2003 Oct; 56(10):736-41. PubMed ID: 14514775
[TBL] [Abstract][Full Text] [Related]
10. Towards a biological staging model for operable non-small cell lung cancer.
O'Byrne KJ; Cox G; Swinson D; Richardson D; Edwards JG; Lolljee J; Andi A; Koukourakis MI; Giatromanolaki A; Gatter K; Harris AL; Waller D; Jones JL
Lung Cancer; 2001 Dec; 34 Suppl 2():S83-9. PubMed ID: 11720747
[TBL] [Abstract][Full Text] [Related]
11. Antigens, receptors and dominant oncogenes and the prognosis of non-small cell lung cancer.
Stahel RA
Lung Cancer; 1994 Nov; 11 Suppl 3():S31-8. PubMed ID: 7704510
[No Abstract] [Full Text] [Related]
12. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients.
Sessa F; Solcia E; Capella C; Bonato M; Scarpa A; Zamboni G; Pellegata NS; Ranzani GN; Rickaert F; Klöppel G
Virchows Arch; 1994; 425(4):357-67. PubMed ID: 7820300
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer.
Lai WW; Chen FF; Wu MH; Chow NH; Su WC; Ma MC; Su PF; Chen H; Lin MY; Tseng YL
Ann Thorac Surg; 2001 Dec; 72(6):1868-76. PubMed ID: 11789762
[TBL] [Abstract][Full Text] [Related]
14. Greater enhancement of chemosensitivity by caffeine in high-p185neu-expressing human non-small-cell lung cancer cell lines.
Tsai CM; Perng RP; Chen MH; Jan YH; Hung MC; Ku TY; Chang KT
J Natl Cancer Inst; 1994 Jul; 86(13):1018-20. PubMed ID: 7911844
[No Abstract] [Full Text] [Related]
15. Biologic and molecular prognostic factors--impact on treatment of patients with non-small cell lung cancer.
Johnson BE
Chest; 1995 Jun; 107(6 Suppl):287S-290S. PubMed ID: 7781407
[TBL] [Abstract][Full Text] [Related]
16. Do molecular markers predict survival in non-small-cell lung cancer?
Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
[TBL] [Abstract][Full Text] [Related]
17. [2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer].
Bréchot JM; Molina T; Theobald S; Depierre A; Lagrange JL; Astoul P; Baldeyrou P; Bardet E; Bazelly B; Breton JL; Douillard JY; Grivaux M; Jacoulet P; Khalil A; Lemarié E; Martinet Y; Massard G; Milleron B; Moro-Sibilot D; Paesmans M; Pujol JL; Quoix AE; Ranfaing E; Rivière A; Sancho-Garnier H; Souquet PJ; Spaeth D; Stcebner-Delbarre A;
Bull Cancer; 2002 Oct; 89(10):857-67. PubMed ID: 12441277
[TBL] [Abstract][Full Text] [Related]
18. Molecular selection trumps clinical selection.
Shepherd FA
J Clin Oncol; 2011 Jul; 29(21):2843-4. PubMed ID: 21670452
[No Abstract] [Full Text] [Related]
19. [The clinical significance of biological characters on non-small cell lung cancer].
Liao M; Lin Z; Zhou Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):30-3. PubMed ID: 11263297
[TBL] [Abstract][Full Text] [Related]
20. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
